A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

ClinicalTrials.gov ID: NCT07609914

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07609914. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 4, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF REDOSING OF RIMEGEPANT IN PARTICIPANTS 18 YEARS OF AGE OR OLDER FOR THE ACUTE TREATMENT OF MIGRAINE

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose of the same medication within the recommended dose limit in people with headache relapse after successful initial treatment of a migraine attack. The primary purpose of this study is to evaluate the safety and tolerability of redosing of rimegepant when taken for the acute treatment of a migraine attack, as it is possible that some patients may benefit from a second dose of rimegepant in this setting.

Study identification

NCT ID: NCT07609914
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 4
Lead sponsor: Pfizer; Industry
Enrollment: 400 participants

Conditions and interventions

Conditions

Acute Treatment of Migraine

Interventions

Rimegepant Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 28, 2026 (Actual)
Primary completion: Jun 7, 2028 (Estimated)
Completion: Jun 7, 2028 (Estimated)
Last update posted: Oct 14, 2026

2026 – 2028

United States locations

U.S. sites: 21
U.S. states: 13
U.S. cities: 19

Facility	City	State	ZIP	Site status
Hope Clinical Research	Canoga Park	California	91303	Recruiting
Neuro-Pain Research Center	Fresno	California	93710	Recruiting
Clinical Research Institute	Los Angeles	California	90048	Recruiting
Neurology Offices of South Florida	Boca Raton	Florida	33428	Recruiting
AppleMedical Research Group, Inc.	Miami	Florida	33126	Recruiting
Brainstorm Research	Miami	Florida	33176	Recruiting
Clinical Neuroscience Solutions	Orlando	Florida	32801	Recruiting
Cedar Crosse Research Center	Chicago	Illinois	60607	Not yet recruiting
Josephson Wallack Munshower Neurology	Indianapolis	Indiana	46256	Not yet recruiting
New England Regional Headache Center	Worcester	Massachusetts	01609	Recruiting
Michigan Headache & Neurological Institute	Ann Arbor	Michigan	48104	Recruiting
Minneapolis Clinic of Neurology - Burnsville Office	Burnsville	Minnesota	55337	Recruiting
Proven Endpoints, LLC	Ridgeland	Mississippi	39157	Recruiting
Alliance Clinical Research Las Vegas (Excel Clinical Research)	Las Vegas	Nevada	89109	Not yet recruiting
M3 Wake Research - Las Vegas Rainbow	Las Vegas	Nevada	89118	Recruiting
Headache Wellness Center	Greensboro	North Carolina	27405	Recruiting
Abington Neurological Associates	Abington	Pennsylvania	19001	Not yet recruiting
FutureSearch Trials of Neurology	Austin	Texas	78731	Recruiting
FutureSearch Trials of Dallas	Dallas	Texas	75251	Recruiting
Red Star Research, LLC	Lake Jackson	Texas	77566	Recruiting
Medstar Health - Department of Neurology	McLean	Virginia	22101	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07609914, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 14, 2026 · Synced Nov 15, 2026